XMD 8-92 is an ERK5 (BMK1) and BRD4 inhibitor (K d of 80 and 190 nM, respectively). Selective for 402 different kinases, also inhibits DCAMKL2, PLK4 and TNK1 (Kd values of 190, 600 and 890 nM). XMD 8-92 has been shown to block growth factor-induced cellular BMK1 activation and reduce BMK1 activity in in vitro kinase assays. XMD 8-92 reduces the BMK1-dependent transactivation activity of MEF2C. Blocks tumor cell proliferation and tumor-associated angiogenesis.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.


![l-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-lHpyrazolo [3,4-d]pyrimidin-l-yl]-l-piperidinyl]-2-propyn-l-one](https://e1752fbe.rocketcdn.me/wp-content/uploads/AP14272-CAS-936563-91-6-1-e1686054563587.png)


